The story so far
edited Oct 23 · 2 paragraphs changedWhat is happening
Roche is seeking to expand its portfolio in multiple sclerosis and breast cancer through new regulatory filings for fenebrutinib and giredestrant 27. The U.S. FDA accepted a New Drug Application for fenebrutinib under priority review on September 30, 2026, for the treatment of relapsing and primary progressive multiple sclerosis 2. This drug is the first BTK inhibitor to receive such a designation from the FDA 2. Data from the FENhance 1 study showed fenebrutinib reduced the annualized relapse rate by 51% compared to teriflunomide in relapsing multiple sclerosis 1415.
updated Oct 23 · 1 earlier version
Added fenebrutinib Phase III FENhance 1 efficacy data [14, 15].
Roche is seeking to expand its portfolio in multiple sclerosis and breast cancer through new regulatory filings for fenebrutinib and giredestrant 27. The U.S. FDA accepted a New Drug Application for fenebrutinib under priority review on September 30, 2026, for the treatment of relapsing and primary progressive multiple sclerosis 2. This drug is the first BTK inhibitor to receive such a designation from the FDA 2.
The FDA set PDUFA goal dates for giredestrant of November 30, 2026, for early-stage breast cancer and December 18, 2026, for advanced disease 13. Results from the Phase III lidERA trial showed giredestrant reduced the risk of invasive disease recurrence or death by 30% compared to standard endocrine therapy in early-stage ER-positive, HER2-negative breast cancer 2122. In advanced disease, the Phase III evERA trial showed a giredestrant-everolimus combination reduced the risk of disease progression or death by 44% in the intention-to-treat population 13. In patients with ESR1-mutated tumors, the combination reduced the risk of progression or death by 62% compared to standard endocrine therapy plus everolimus 13.
updated Oct 23 · 1 earlier version
Added lidERA trial results for early-stage breast cancer [21, 22].
The FDA set PDUFA goal dates for giredestrant of November 30, 2026, for early-stage breast cancer and December 18, 2026, for advanced disease 13. Results from the Phase III evERA trial showed a giredestrant-everolimus combination reduced the risk of disease progression or death by 44% in the intention-to-treat population 13. In patients with ESR1-mutated tumors, the combination reduced the risk of progression or death by 62% compared to standard endocrine therapy plus everolimus 13.
New PDUFA dates and Phase III evERA trial results for giredestrant [13].
What to watch
An FDA decision on the fenebrutinib application would settle the approval status for the drug in the United States 2. A final decision from the European Commission would confirm the approval of Ocrevus for pediatric patients aged 10 and older following a positive recommendation from the CHMP on September 18, 2026 3. The start of commercial launches for fenebrutinib in the U.S. and Ocrevus for pediatric use in the EU would follow these respective regulatory actions 23. FDA action by the PDUFA dates of November 30, 2026, and December 18, 2026, would settle the marketing status of giredestrant in the U.S. 13.
last changed Oct 22 · 1 earlier version
Added specific PDUFA dates for giredestrant as upcoming milestones [13].
An FDA decision on the fenebrutinib application would settle the approval status for the drug in the United States 2. A final decision from the European Commission would confirm the approval of Ocrevus for pediatric patients aged 10 and older following a positive recommendation from the CHMP on September 18, 2026 3. The start of commercial launches for fenebrutinib in the U.S. and Ocrevus for pediatric use in the EU would follow these respective regulatory actions 23. In breast cancer, the design of a new Phase III study for giredestrant as an adjuvant treatment follows the failure of the persevERA trial to meet its primary endpoint in June 2026 4.
Read the full brief · how we got here
How we got here
The FDA previously approved Itovebi on October 11, 2024, for use in a triple therapy regimen for specific types of advanced breast cancer 1. The European Commission approved the same drug for PIK3CA-mutated, ER-positive, HER2-negative advanced breast cancer in July 2025 9. For multiple sclerosis, the FDA approved Ocrevus for pediatric patients in May 2026, prior to the recent European regulatory progress 3.
References · 11
- 1pharmaphorum.com — Roche gets FDA green light for breast cancer drug Itovebi
- 2roche.com — Roche's fenebrutinib is the first BTK inhibitor to receive U.S. FDA ...
- 3roche.com — CHMP recommends EU approval of Roche's Ocrevus for children and ...
- 4fiercebiotech.com — ASCO: Roche, head held high, details oral SERD's first-line flop in ...
- 7roche.com — FDA accepts New Drug Application for Roche's giredestrant in ER ...
- 9roche.com — European Commission approves Roche's Itovebi for people with ER ...
- 13roche.com — Roche's giredestrant combination significantly improved progression ...
- 14roche.com — [Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (...
- 15pharmaphorum.com — After phase 3 clean sweep, Roche plans oral BTK filing in MS | pharmaphorum
- 21ainvest.com — Roche at ESMO 2026: Three Pipeline Reads, One Growth Question
- 22swissobserver.ch — Breakthrough: Roche Reports Positive Results in Breast Cancer Treatment ...
What would close this
0 of 4 metTimeline
3newest firstPhase III lidERA trial data shows giredestrant reduces early-stage breast cancer recurrence risk by 30%
New data from the Phase III lidERA trial involving 4,100 patients demonstrates that giredestrant reduces the risk of invasive disease recurrence or death by 30% compared to standard endocrine therapy in early-stage ER-positive, HER2-negative breast cancer. These findings support the pending FDA decision for the drug's use in early-stage disease, currently scheduled for November 30, 2026.
- The lidERA trial showed a three-year invasive disease-free survival rate of 92.4% for giredestrant versus 89.6% for standard treatment 3.
- Roche confirmed that the final Phase III readout for fenebrutinib (FENhance 1) showed a 51% reduction in annualized relapse rates for relapsing multiple sclerosis, completing the data package for global regulatory submissions 1, 10.
Full analysiswritten from the full pages behind this update
What happened
Roche presented patient-reported outcomes from the Phase III lidERA trial at the ESMO Annual Meeting on October 23, 2026 3, 8. The data showed that giredestrant reduced the risk of invasive disease recurrence or death by 30% compared to standard endocrine therapy in patients with early-stage ER-positive, HER2-negative breast cancer 3. At the three-year mark, 92.4% of patients receiving giredestrant were alive and free of invasive disease, compared to 89.6% in the standard treatment group 3. Roche reported that these results were achieved without compromising patient quality of life or tolerability 3.
In advanced disease settings, the Phase III evERA trial demonstrated that a combination of giredestrant and everolimus reduced the risk of disease progression or death by 44% in the intention-to-treat population 3. Among patients with ESR1-mutated tumors, the combination reduced this risk by 62% compared to standard endocrine therapy plus everolimus 3. However, the Phase III persevERA trial, which tested giredestrant plus Ibrance as a frontline treatment, failed to meet its primary endpoint of delaying disease progression or death compared to Ibrance plus hormone therapy 7.
For multiple sclerosis (MS), Roche completed the Phase III clinical development program for fenebrutinib following the FENhance 1 study readout 1. Fenebrutinib reduced the annualized relapse rate (ARR) by 51% compared to teriflunomide in relapsing MS (RMS) 1. This followed FENhance 2 results showing a 59% reduction in ARR and positive results from the FENtrepid study in primary progressive MS (PPMS) 1. Across the FENhance studies, eight fatalities occurred in the fenebrutinib arms compared to one in the teriflunomide arm; Roche stated these had various causes and occurred at different points in treatment 1, 2.
Why it matters
The regulatory decisions pending for giredestrant and fenebrutinib will determine Roche's ability to capture share in the oral SERD and BTK inhibitor markets. Bloomberg estimates giredestrant could generate up to $15 billion in revenue 3, 5. The drug is positioned to compete with AstraZeneca’s camizestrant, which is also under FDA review 7, 8. While giredestrant showed efficacy in early-stage and advanced settings, the failure of the persevERA trial in frontline treatment has led analysts at Jefferies to question its multibillion-dollar potential 7.
Fenebrutinib is the first BTK inhibitor to receive FDA priority review for MS 1. If approved, it would be the only high-efficacy oral treatment for both RMS and PPMS 1. The drug's safety profile, specifically the eight fatalities and one case of Hy’s Law (asymptomatic liver transaminase elevation) in the FENhance 1 study, will face regulatory scrutiny 1, 2. Competitor Sanofi previously faced an FDA rejection for its BTK inhibitor, tolebrutinib, in non-relapsing secondary progressive MS due to liver toxicity concerns 2.
What's next
The FDA has set the following PDUFA goal dates for giredestrant:
- November 30, 2026: Decision on giredestrant as an adjuvant treatment for stage I to III ER-positive, HER2-negative breast cancer 3.
- December 18, 2026: Decision on the giredestrant-everolimus combination for advanced breast cancer 3.
For fenebrutinib, an FDA decision will follow the priority review accepted on September 30, 2026. A final decision from the European Commission is expected to settle the approval of Ocrevus for pediatric patients aged 10 and older, following the positive CHMP recommendation issued on September 18, 2026. The ESMO Annual Meeting continues through October 27, 2026, where Roche is scheduled to present additional biomarker findings from the evERA trial 3, 8.
FDA sets December PDUFA date for giredestrant in advanced breast cancer
Roche announced that the FDA set PDUFA goal dates for giredestrant of November 30, 2026, in early-stage breast cancer and December 18, 2026, for advanced disease 4. The company also published Phase III evERA study results showing the giredestrant-everolimus combination reduced the risk of disease progression or death by 44% in the intention-to-treat population 4.
- Detailed results from the evERA trial, published in the New England Journal of Medicine, demonstrate a 62% reduction in risk of progression or death for patients with ESR1-mutated tumors compared to standard endocrine therapy plus everolimus 4.
- The FDA accepted a New Drug Application for fenebrutinib under priority review for both relapsing and primary progressive multiple sclerosis, based on data from the FENhance 1 and 2 and FENtrepid Phase III studies 5.
Full analysiswritten from the full pages behind this update
What happened
The U.S. FDA accepted a New Drug Application for fenebrutinib under priority review for the treatment of relapsing and primary progressive multiple sclerosis 5. This filing is the first BTK inhibitor to receive such a designation for both MS indications 5. The application is supported by Phase III data from the FENhance 1 and 2 studies, where fenebrutinib reduced the annualized relapse rate by 51.1% and 58.5% respectively compared to teriflunomide 5. In the FENtrepid study for primary progressive MS, fenebrutinib met its primary endpoint of non-inferiority to Ocrevus, numerically reducing the risk of disability progression by 12% 5.
In breast cancer, the FDA set PDUFA goal dates for giredestrant of November 30, 2026, for early-stage disease and December 18, 2026, for advanced disease 4. Detailed results from the Phase III evERA trial, published in the New England Journal of Medicine, showed that giredestrant plus everolimus reduced the risk of disease progression or death by 44% in the intention-to-treat population and 62% in patients with ESR1-mutated tumors 4. The EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion in September 2026 recommending an extension of indication for Ocrevus 8.
Why it matters
The regulatory progress for fenebrutinib and giredestrant is central to Roche’s strategy to drive revenue growth in 2027 7. If approved, fenebrutinib would become the first high-efficacy oral therapy available for both relapsing and primary progressive MS 5. The drug is designed to cross the blood-brain barrier to target chronic inflammation, which is thought to drive long-term disability progression 5. In the FENhance studies, patients treated with fenebrutinib experienced approximately one relapse every 17 years, the lowest rate recorded in Phase III MS trials 5.
For breast cancer, giredestrant aims to address endocrine therapy resistance, which affects approximately 70% of hormone receptor-positive, HER2-negative cases 4. The evERA trial results suggest the giredestrant-everolimus combination could provide an all-oral treatment option that delays disease progression more effectively than standard endocrine therapy 4. Market competition in MS includes subcutaneous Ocrevus Zunovo, which received FDA approval in September 2024 to compete with monthly self-injections and other infused therapies 6.
What's next
The FDA is scheduled to act on the giredestrant applications by the PDUFA dates of November 30, 2026, and December 18, 2026 4. A final decision from the European Commission would settle the marketing authorization for the Ocrevus indication extension following the September CHMP recommendation 8.
For fenebrutinib, the priority review status indicates an accelerated timeline for an FDA decision on the New Drug Application 5. Follow-up for overall survival in the giredestrant evERA trial will continue until the next planned analysis, as current data shows a positive trend but remains immature 4. Commercial launches for these therapies would follow the respective regulatory approvals in the U.S. and EU.
When we started following: FDA grants priority review to Roche's fenebrutinib for MS as Ocrevus awaits European Commission decision for pediatric use
The U.S. FDA accepted Roche’s New Drug Application for fenebrutinib under priority review on September 30, 2026, for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) 2. The filing is supported by Phase III data from the FENhance 1 and 2 studies and the FENtrepid study, which showed fenebrutinib slowed disability progression in PPMS 2.
In pediatric MS, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Ocrevus (ocrelizumab) for patients aged 10 and older on September 18, 2026 3. This follows U.S. FDA approval for the same pediatric population in May 2026 3. A final decision from the European Commission is expected in the near future 3.
In breast cancer, Roche is designing a new Phase III study for giredestrant as an adjuvant treatment for early-stage breast cancer following a June 2026 report on the persevERA trial, which failed its primary endpoint in first-line metastatic disease 4. Previously, the FDA approved Itovebi (inavolisib) on October 11, 2024, for use in triple therapy for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer 1.